The resolution encourages the Alabama Medicaid Agency to assess the overall costs associated with GLP-1 medications, which are used for weight management, and to report its findings to the Legislature before the 2027 Legislative Session. It highlights the significant impact of obesity on health and economic factors in Alabama, noting that obesity-related medical expenditures in the U.S. reached nearly $173 billion annually, with Alabama's GDP negatively affected by $7.2 billion. The resolution also points out that approximately 110,000 individuals in Alabama may qualify for GLP-1 medications based on current FDA labeling.

The resolution outlines specific actions for the Alabama Medicaid Agency, including determining potential savings from covering GLP-1 medications, evaluating costs in light of new drug pricing models, and engaging with healthcare providers and stakeholders to improve health outcomes and cost efficiency. The goal is to ensure that any coverage decisions made will benefit both the health of Alabamians and the state's budget.